A comprehensive review on the indazole based derivatives as targeted anticancer agents

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Journal of Molecular Structure

• Publication date

  2023-03-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.molstruc.2023.135327
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2022

  2022cited by this paper
• Indazole-based microtubule-targeting agents as potential candidates for anticancer drugs discovery.

  2022cited by this paper
• Facile synthesis of new N1-alkylated 1H-indazole-3-carboxamide derivatives as potential anticancer agents: in vitro, ADMET prediction, and SAR studies

  2022cited by this paper
• Indole Derivatives as New Structural Class of Potent and Antiproliferative Inhibitors of Monocarboxylate Transporter 1 (MCT1; SLC16A1)

  2022cited by this paper
• Design, synthesis and biological evaluation of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors.

  2021cited by this paper
• Discovery of Novel Benzimidazole and Indazole Analogues as Tubulin Polymerization Inhibitors with Potent Anticancer Activities.

  2021cited by this paper
• Design, synthesis and biological evaluation of 1H-indazole derivatives as novel ASK1 inhibitors.

  2021cited by this paper
• Synthesis and biological evaluation of indazole derivatives as anti-cancer agents

  2021cited by this paper
• Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.

  2021cited by this paper
• Antiproliferative and apoptotic activity of new indazole derivatives as potential anticancer agents

  2020cited by this paper
• Study on Pd(PPh3)4 Catalyzed Synthesis of Indazole Derivatives as Potent Anticancer Drug

  2020cited by this paper
• Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer.

  2020cited by this paper
• Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: A review with structure-activity relationship insights.

  2020cited by this paper
• Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications

  2019cited by this paper
• The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo.

  2019cited by this paper
• Co-incidence of RCC-susceptibility polymorphisms with HIF cis-acting sequences supports a pathway tuning model of cancer

  2019cited by this paper
• Heterocycles in Medicinal Chemistry

  2019cited by this paper
• Monocarboxylate transporters in cancer

  2019cited by this paper
• Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

  2019cited by this paper
• Role for polo-like kinase 4 in mediation of cytokinesis

  2019cited by this paper
• 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.

  2019cited by this paper
• Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis.

  2019cited by this paper
• Recent Advances and Developments of in vitro Evaluation of Heterocyclic Moieties on Cancer Cell Lines.

  2018cited by this paper
• A patent review of IDO1 inhibitors for cancer

  2018cited by this paper
• PLK4: a link between centriole biogenesis and cancer

  2018cited by this paper
• Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers

  2018cited by this paper
• Challenges in Treating Estrogen Receptor-Positive Breast Cancer

  2018cited by this paper
• YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect

  2018cited by this paper
• The functional diversity of Aurora kinases: a comprehensive review

  2018cited by this paper
• Targeting the IDO1 pathway in cancer: from bench to bedside

  2018cited by this paper
• Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies

  2018cited by this paper
• Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs

  2018cited by this paper
• Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors.

  2017cited by this paper
• Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.

  2017cited by this paper
• Identification of Substituted 1H‐Indazoles as Potent Inhibitors for Immunosuppressive Enzyme Indoleamine 2,3‐Dioxygenase 1

  2017cited by this paper
• A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer

  2017cited by this paper
• Mechanisms that Increase Stability of Estrogen Receptor Alpha in Breast Cancer

  2017cited by this paper
• Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.

  2017cited by this paper
• Sulfocoumarin‐, Coumarin‐, 4‐Sulfamoylphenyl‐Bearing Indazole‐3‐carboxamide Hybrids: Synthesis and Selective Inhibition of Tumor‐Associated Carbonic Anhydrase Isozymes IX and XII

  2017cited by this paper
• Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold.

  2017cited by this paper
• MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

  2017cited by this paper
• Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.

  2017cited by this paper
• Synthesis and Molecular Modeling Studies of N′-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors

  2017cited by this paper
• Discovery of IDO1 Inhibitors: From Bench to Bedside.

  2017cited by this paper
• Discovery and preliminary structure-activity relationship of 1H-indazoles with promising indoleamine-2,3-dioxygenase 1 (IDO1) inhibition properties.

  2016cited by this paper
• Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.

  2016cited by this paper
• Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design.

  2016cited by this paper
• Targeting Protein–Protein Interactions in the HIF System

  2016cited by this paper
• Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors

  2016cited by this paper
• Pim-3 is a Critical Risk Factor in Development and Prognosis of Prostate Cancer

  2016cited by this paper
• The intricacies of the stacking interaction in a pyrrole–pyrrole system

  2016cited by this paper
• The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters.

  2016cited by this paper
• Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold.

  2015cited by this paper
• Elevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer.

  2015cited by this paper
• Aurora kinase A in gastrointestinal cancers: time to target

  2015cited by this paper
• Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications

  2015cited by this paper
• PLK4 trans-Autoactivation Controls Centriole Biogenesis in Space.

  2015cited by this paper
• Plk4-dependent phosphorylation of STIL is required for centriole duplication

  2015cited by this paper
• The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.

  2015cited by this paper
• Aurora A overexpression in breast cancer patients induces taxane resistance and results in worse prognosis.

  2015cited by this paper
• Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines.

  2015cited by this paper
• Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use.

  2015cited by this paper
• Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.

  2015cited by this paper
• Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

  2015cited by this paper
• The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors.

  2015cited by this paper
• Novel potent HIF-1 inhibitors for the prevention of tumor metastasis: discovery and optimization of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives

  2015cited by this paper
• Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors.

  2015cited by this paper
• Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.

  2015cited by this paper
• BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma

  2014cited by this paper
• Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential.

  2014cited by this paper
• Lactate transporters and vascular factors in HPV-induced squamous cell carcinoma of the uterine cervix

  2014cited by this paper
• p53-Dependent and Cell Specific Epigenetic Regulation of the Polo-like kinases under Oxidative Stress

  2014cited by this paper
• Anticancer metallodrugs of glutamic acid sulphonamides: in silico, DNA binding, hemolysis and anticancer studies

  2014cited by this paper
• Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion

  2014cited by this paper
• Synthesis and Antitumor Activity of Some Substituted Indazole Derivatives

  2014cited by this paper
• SAPK pathways and p53 cooperatively regulate PLK4 activity and centrosome integrity under stress

  2013cited by this paper
• Identification of pyrrolo[2,3-g]indazoles as new Pim kinase inhibitors.

  2013cited by this paper
• Synthesis, DNA binding, hemolysis assays and anticancer studies of copper(II), nickel(II) and iron(III) complexes of a pyrazoline-based ligand.

  2013cited by this paper
• Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.

  2013cited by this paper
• Glutamic acid and its derivatives: candidates for rational design of anticancer drugs.

  2013cited by this paper
• Assessment of Aurora a Kinase Expression in Breast Cancer: A Tool for Early Diagnosis?

  2013cited by this paper
• Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant.

  2013cited by this paper
• Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.

  2013cited by this paper
• Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125).

  2013cited by this paper
• Syntheses, DNA binding and anticancer profiles of L-glutamic acid ligand and its copper(II) and ruthenium(III) complexes.

  2012cited by this paper
• Synthesis, antiproliferative and apoptotic activities of N-(6(4)-indazolyl)-benzenesulfonamide derivatives as potential anticancer agents.

  2012cited by this paper
• Proviral Integration Site for Moloney Murine Leukemia Virus (PIM) Kinases Promote Human T Helper 1 Cell Differentiation

  2012cited by this paper
• The monocarboxylate transporter family—Role and regulation

  2012cited by this paper
• (Z)-1-aryl-3-arylamino-2-propen-1-ones, highly active stimulators of tubulin polymerization: synthesis, structure-activity relationship (SAR), tubulin polymerization, and cell growth inhibition studies.

  2012cited by this paper
• Gene amplification and overexpression of Aurora-C in breast and prostate cancer cell lines.

  2012cited by this paper
• Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90.

  2012cited by this paper
• Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent.

  2011cited by this paper
• Interfering with pH regulation in tumours as a therapeutic strategy

  2011cited by this paper
• Hybrid compounds as new Bcr/Abl inhibitors.

  2011cited by this paper
• Design, synthesis and insight into the structure-activity relationship of 1,3-disubstituted indazoles as novel HIF-1 inhibitors.

  2011cited by this paper
• Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors.

  2011cited by this paper
• BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.

  2010cited by this paper
• Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2

  2010cited by this paper
• Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

  2010cited by this paper
• Mechanisms of multidrug resistance in cancer.

  2010cited by this paper

• Organophotocatalytic Oxidative Annulation of Phosphoryl Arylhydrazones to Access Indazoles.

  2026cites this paper
• Indazole, a privileged scaffold: Synthetic strategies, biological potential, and future prospects

  2026cites this paper
• Design and Synthesis of Novel Indazole—Sulfonamide Derivatives, Cytotoxicity, and Molecular Docking Insights

  2026cites this paper
• Computational study on the Structural and Spectroscopic Properties, Solvent Effects, Topological Insights, and Biological Activities of 2-[1-(2, 4-dichlorobenzyl)-1H-indazol-3-yl] Propan-2-ol as an Anticonvulsant Drug

  2025cites this paper
• Exploration of Indazole-Derived Oxadiazoles and Thiadiazoles as Potential Antimycobacterial Agents: Synthesis and In Silico Docking Analysis

  2025cites this paper
• I2/DMSO Mediated [5+1] Oxidative Annulation of Aryl Methyl Ketones with 2‐(2H‐Indazol‐2‐yl)anilines for the Synthesis of Indazoloquinoxalines

  2025cites this paper
• Rh(III)-Catalyzed Fabrication of [4,3,1]-Bridged Azaheterocycles using Quinone Monoacetals.

  2025cites this paper
• Design, synthesis, and antiproliferative activity of new 5-ethylsulfonyl-indazole-3-carbohydrazides as dual EGFR/VEGFR-2 kinases inhibitors

  2025cites this paper
• Recent Advances in Synthetic Strategies and Biological Properties of Indazole Scaffolds: A Review

  2025cites this paper
• Visible‐light‐mediated synthesis of 2H-indazoles from (2-Bromo-benzylidene)-phenyl-amine derivatives by the Ullmann Goldberg reaction.

  2025cites this paper
• The Role of Flow Chemistry on the Synthesis of Pyrazoles, Pyrazolines and Pyrazole-Fused Scaffolds

  2025cites this paper
• Characterization of the Degradation and Nitrogenous Disinfection Byproduct Formation of Nitrogen-Containing Benzoheterocyclic Compounds during the UV-LED (275 nm)/Chlorine Process: Roles of Reactive Species and Pathway of Dichloroacetonitrile Formation.

  2025cites this paper
• Rapid Synthesis of Indazole derivatives using Microwave Technology, its Characterisation and Anti-Inflammatory effects Observed in Laboratory Tests

  2025cites this paper
• In-silico Analysis and Molecular Modeling of Tropomycin Receptor Kinase Inhibitors as an Anticancer agents

  2025cites this paper
• Synthesis, Characterization, Antimicrobial Activity and Molecular Modeling Studies of Novel Indazole-Benzimidazole Hybrids

  2025cites this paper
• Linear triazenes: Versatile scaffolds for chemical biology and drug design.

  2025cites this paper
• Design, Synthesis, Anticancer and Antimicrobial Evaluation and In Silico Study of Indazole – Pyrimidine – 1,2,3-Triazole Hybrids

  2025cites this paper
• Synthesis, structure of the N-(Alkyl/Arylsulfonyl) substituted 5-(Bromo/Iodo)-3-methylindazoles and bioactivity screening against some of the biochemical targets linked to type 2 diabetes mellitus

  2024cites this paper
• Design, synthesis, biological evaluation and molecular docking study of new pyrazolo[1,5-a]pyrimidines as PIM kinase inhibitors and apoptosis inducers

  2024cites this paper
• Copper-Catalyzed Hydroamination of 2-Alkynylazobenzenes: Synthesis of 3-Alkenyl-2H-Indazoles

  2024cites this paper
• A Convenient Synthesis of 1,2,4-Triazino[2,3-b]indazol-3-amine Derivatives via Tandem Abnormal Staudinger/Aza-Wittig/Isomerization Reaction

  2023cites this paper
• Indazole–Pyridine Hybrids: Design, Synthesis, and Biological Evaluation as Possible Anticancer Agents against Breast Cancer Cell Lines

  year unknowncites this paper